Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation

• Published in: Zhōnghuá xuèyèxué zázhì 2022-07, Vol.43 (7), p.542-549
• Main Authors: Chen, X, Liu, Z Y, Zhang, R L, Zhai, W H, Ma, Q L, Pang, A M, Yang, D L, He, Y, Wei, J L, Feng, S Z, Han, M Z, Jiang, E L
• Format: Article
• Language: Chinese
• Subjects: Adolescent; Adult; Chronic Disease; Female; Hematologic Neoplasms - therapy; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute - pathology; Leukemia, Myeloid, Acute - therapy; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Prognosis; Recurrence; Retrospective Studies; Transplantation, Homologous; Young Adult
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2022.07.003

To investigate the efficacy and safety of preemptive/salvage therapy with venetoclax (VEN) in patients with recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Retrospective analysis the clinical data of 25 patients with minimal residual disease (MRD) positive or morphological recurrence after allo-HSCT treated with VEN in the hematological Hospital of Chinese Academy of Medical Sciences from 2021.2 to 2021.11, there were 15 MRD positive patients (preemptive treatment group) and 10 morphological recurrence patients (salvage treatment group) . The dose of VEN in both groups was 400 mg/d, which was reduced to 100 mg/d when combined with azole antifungal drugs. ①In the preemptive group, there were 7 males and 8 females, with a median age of 32 (18-52) years; There were 13 cases of acute myeloid leukemia (AML) , 1 case of acute lymphoblastic leukemia (ALL) and 1 case of primary myelofibrosis (PMF) ; the median time from MRD positive to the application of VEN was 2.5 (0-12.5) months.